09:33 AM EDT, 05/30/2024 (MT Newswires) -- Day One Biopharmaceuticals ( DAWN ) said Thursday it sold its priority review voucher for $108 million to an undisclosed buyer.

The company said it was awarded the voucher after the US Food and Drug Administration's accelerated approval of Ojemda, or tovorafenib.

As part of the deal, $8.1 million of the amount received from the sale of the voucher will be paid to Viracta Therapeutics to satisfy voucher-related obligations under Day One's 2019 license agreement with Viracta, the company said.

Price: 14.00, Change: +0.24, Percent Change: +1.74